Table 9.
The relationship between the development of rash and clinical outcome when using anti-EGFR mAbs in mCRC.
| Trial (first author) | KRAS | Protocol | Grade of rash | Results | HR (95% CI) | P value | |
|---|---|---|---|---|---|---|---|
| PFS | OS | ||||||
| — (O'Callaghan et al.) [44] | WT | BSC versus | 0/1 | 1.9 mos. | 5 mos. | PFS: 0.57 (0.38–0.86) OS: 0.85 (0.56–1.31) |
0.008 0.46 |
| cetuximab |
2.2 mos. |
8 mos. |
|||||
| WT | BSC versus | 2+ | 1.9 mos. | 5 mos. | PFS: 0.32 (0.21–0.49) OS: 0.52 (0.34–0.8) |
<0.001 0.003 |
|
| cetuximab | 5.1 mos. | 9.8 mos. | |||||
| MUT | BSC versus | 0/1 | 1.9 mos. | 5 mos. | PFS: 0.97 (0.65–1.46) OS: 1.47 (0.95–2.27) |
0.89 0.08 |
|
| cetuximab |
1.8 mos. | 4.0 mos. | |||||
| MUT | BSC versus | 2+ | 1.9 mos. | 5 mos. | PFS: 0.82 (0.52–1.3) OS: 0.82 (0.47–1.41) |
0.89 0.46 |
|
| cetuximab | 1.8 mos. | 6.6 mos. | |||||
WT: wild type, MUT: mutated, PFS: progression-free survival, and OS: overall survival.